<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04521647</url>
  </required_header>
  <id_info>
    <org_study_id>2000028570</org_study_id>
    <secondary_id>1K01DA051882-01</secondary_id>
    <nct_id>NCT04521647</nct_id>
  </id_info>
  <brief_title>Effects of Menthol in E-cigarettes on Smoking Behaviors</brief_title>
  <official_title>Effects of Menthol in E-cigarettes on Smoking Behaviors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of this proposal is to understand the relationship between nicotine&#xD;
      metabolism and menthol flavor in e-cigarettes on smoking behavior in smokers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Anticipated">July 2025</completion_date>
  <primary_completion_date type="Anticipated">July 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cigarette craving</measure>
    <time_frame>up to 3 weeks</time_frame>
    <description>Labeled Magnitude Scale ; -100 (no sensation) to 100 (strongest imaginable)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma nicotine levels</measure>
    <time_frame>up to 3 weeks</time_frame>
    <description>blood samples obtained at baseline and 2, 5, 15, 30, 45, 60, 90, 120, and 180 minutes after nicotine exposure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Carbon monoxide</measure>
    <time_frame>up to 2 weeks</time_frame>
    <description>breath carbon monoxide will be assessed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>e-cigarette craving</measure>
    <time_frame>up to 3 weeks</time_frame>
    <description>Labeled Magnitude Scale ; -100 (no sensation) to 100 (strongest imaginable)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>irritation/harshness</measure>
    <time_frame>up to 3 weeks</time_frame>
    <description>Labeled Magnitude Scale ; -100 (no sensation) to 100 (strongest imaginable)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>liking of e-cigarette</measure>
    <time_frame>up to 3 weeks</time_frame>
    <description>Labeled Hedonic Scale ; -100 (most disliked) to 100 (most liked)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>coolness</measure>
    <time_frame>up to 3 weeks</time_frame>
    <description>Labeled Magnitude Scale ; -100 (no sensation) to 100 (strongest imaginable)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>nicotine withdrawal</measure>
    <time_frame>up to 3 weeks</time_frame>
    <description>Drug effect questionnaire; 0(&quot;not at all&quot;) to 100(&quot;extremely&quot;) mm scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stimulation</measure>
    <time_frame>up to 3 weeks</time_frame>
    <description>Drug effect questionnaire: 0(&quot;not at all&quot;) to 100(&quot;extremely&quot;) mm scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>liking of e-cigarette</measure>
    <time_frame>up to 3 weeks</time_frame>
    <description>Drug effect questionnaire: 0(&quot;not at all&quot;) to 100(&quot;extremely&quot;) mm scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>e-cigarette use</measure>
    <time_frame>up to 2 weeks</time_frame>
    <description>time line follow back</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cigarette use</measure>
    <time_frame>up to 2 weeks</time_frame>
    <description>timeline follow back</description>
  </secondary_outcome>
  <other_outcome>
    <measure>heart rate</measure>
    <time_frame>up to 5 weeks</time_frame>
    <description>beats per minute</description>
  </other_outcome>
  <other_outcome>
    <measure>blood pressure</measure>
    <time_frame>up to 5 weeks</time_frame>
    <description>diastolic and systolic measurements</description>
  </other_outcome>
  <other_outcome>
    <measure>pulse oximetry</measure>
    <time_frame>up to 5 weeks</time_frame>
    <description>measurement of oxygen in blood</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">85</enrollment>
  <condition>Nicotine Dependence</condition>
  <arm_group>
    <arm_group_label>menthol flavor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 5% nicotine in an e-cigarette</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tobacco flavor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 5% nicotine in an e-cigarette</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine</intervention_name>
    <description>Participants will receive two nicotine concentrations via e-cigarettes. Each exposure will be 10 3-sec puffs and ad libitum use</description>
    <arm_group_label>menthol flavor</arm_group_label>
    <arm_group_label>tobacco flavor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 21 years old, able to read and write, use of cigarettes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Asti Jackson, PhD</last_name>
    <phone>4752414904</phone>
    <email>asti.jackson@yale.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pierce Laboratory</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie DeFrank</last_name>
      <phone>203-562-9901</phone>
      <phone_ext>270</phone_ext>
      <email>melanie.defrank@yale.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>August 1, 2020</study_first_submitted>
  <study_first_submitted_qc>August 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2020</study_first_posted>
  <last_update_submitted>April 9, 2021</last_update_submitted>
  <last_update_submitted_qc>April 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Asti Jackson</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

